EUVIMEDEUVIMED entdecken
Crossref

99mTc-HYNIC-PSMA-11 whole-body SPECT/CT: a clinically viable alternative to 68Ga-PSMA PET/CT in patients with prostate cancer

Monika Hooda, Komalpreet Kaur, Ankit Watts, Harmandeep Singh, Harneet Kaur, Vinisha Gunasekaran, Aditya P Sharma, Ravimohan Mavuduru, Baljinder Singh iD

British Journal of Radiology · 01.06.2026 · 99 (1182) · 1081-1091

DOI: 10.1093/bjr/tqag052 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Radiology, online erschienen am 12.03.2026. Verfasst von Monika Hooda und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh 160012, India. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Whole Body Imaging, Positron Emission Tomography Computed Tomography, Radiopharmaceuticals. Die Arbeit nennt 36 Literaturangaben. Gefördert von: DST-SERB.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The diagnostic performance of 99mTc-HYNIC-PSMA-11 whole-body SPECT/CT versus 68Ga-PSMA PET/CT was evaluated in prostate cancer patients.

Methods

As a part of the diagnostic workup, all the prostate cancer (PCa) patients (n = 10; mean age 66.4 ± 9.6 years) underwent whole-body 68Ga-PSMA-11 PET/CT followed by serial whole-body (anterior and posterior) 99mTc-HYNIC-PSMA-11 imaging The serial whole-body imaging was performed at multiple time points of 10 minutes, 2 hours, 4 hours, 6 hours, 24 hours and the whole-body SPECT/CT was acquired at 3 hours. The whole-body SPECT/CT data was analysed for lesions detection and to calculate the standardized uptake values (SUVmax) for 99mTc-HYNIC-PSMA-11 avid lesions using the Q-Metrix software. These values were compared with the corresponding SUVmax values obtained from 68Ga-PSMA-11 PET/CT. The serial whole-body imaging data were used for estimating the radiation absorbed doses (mSv/MBq) to various organs using the MIRD schema and the OLINDA/EXM software.

Results

68Ga-PSMA-11 PET/CT identified a total of 64 metastatic lesions, while 99mTc-HYNIC-PSMA-11 SPECT/CT detected 49/64 metastatic lesions, presenting a sensitivity of 76.6%. Notably, the mean SUVmax values for 68Ga-PSMA-11 PET/CT and 99mTc-HYNIC-PSMA-11 were comparable and a highly significant positive correlation (r > 0.93; P < .01) The average absorbed doses to the salivary glands, lungs, kidneys, urinary bladder, and liver were found to be comparable with 99mTc-MDP bone scanning.

Conclusions

The diagnostic performance of whole-body 99mTc-HYNIC PSMA-11 SPECT/CT is fairly comparable to 68Ga-PSMA PET/CT and offers a favourable dosimetry indicating its potential for PCa evaluation. Advances in knowledge 99mTc-PSMA-11 SPECT/CT may be an alternative and cost-effective tool for evaluation of initial PSMA disease burden as well as for response evaluation to PSMA targeted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsWhole Body ImagingPositron Emission Tomography Computed TomographyRadiopharmaceuticalsEdetic AcidOrganotechnetium CompoundsOligopeptidesSingle Photon Emission Computed Tomography Computed TomographyHumansMaleGallium RadioisotopesAgedGallium IsotopesMiddle AgedSensitivity and Specificity

Stichwörter der Autor:innen

68Ga-PSMA-11 PET/CT99mTc-HYNIC-PSMA-11OLINDAQ-metrixSUVmax SPECT and SUVmaxdosimetry toolkitwhole-body serial imaging/SPECT/CT

Substanzen

Gallium RadioisotopesGallium Isotopesgallium 68 PSMA-11RadiopharmaceuticalsEdetic AcidOrganotechnetium CompoundsOligopeptidesPSMA-11

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh 160012, India.
  • Department of Urology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh 160012, India.

ORCID-Profile: Baljinder Singh

Förderung

  • DST-SERB

Zitieren

APA

Hooda, M., Kaur, K., Watts, A., Singh, H., Kaur, H., Gunasekaran, V., Sharma, A. P., Mavuduru, R., & Singh, B. (2026). 99mTc-HYNIC-PSMA-11 whole-body SPECT/CT: a clinically viable alternative to 68Ga-PSMA PET/CT in patients with prostate cancer. British Journal of Radiology, 99(1182), 1081-1091. https://doi.org/10.1093/bjr/tqag052

Vancouver

Hooda M, Kaur K, Watts A, Singh H, Kaur H, Gunasekaran V, et al. 99mTc-HYNIC-PSMA-11 whole-body SPECT/CT: a clinically viable alternative to 68Ga-PSMA PET/CT in patients with prostate cancer. British Journal of Radiology. 2026;99(1182):1081-1091. doi:10.1093/bjr/tqag052

BibTeX
@article{Hooda2026,
  author = {Hooda, Monika and Kaur, Komalpreet and Watts, Ankit and Singh, Harmandeep and Kaur, Harneet and Gunasekaran, Vinisha and Sharma, Aditya P and Mavuduru, Ravimohan and Singh, Baljinder},
  title = {99mTc-HYNIC-PSMA-11 whole-body SPECT/CT: a clinically viable alternative to 68Ga-PSMA PET/CT in patients with prostate cancer},
  journal = {British Journal of Radiology},
  year = {2026},
  volume = {99},
  number = {1182},
  pages = {1081--1091},
  doi = {10.1093/bjr/tqag052}
}
Kostenlos starten →